PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application Number 10/076,905 Filing Date TRANSMITTAL February 14, 2002 First Named Inventor **FORM** Ze'ev Ronai Art Unit 1642 (to be used for all correspondence after initial filing) Examiner Name S. L. Rawlings Attorney Docket Number Total Number of Pages in This Submission 29 02420/100I249-US2 ENCLOSURES (Check all that apply) After Allowance Communication x Fee Transmittal Form Drawing(s) Appeal Communication to Board of x Fee Attached Licensing-related Papers Appeals and Interferences Appeal Communication to TC Amendment/Reply Petition (Appeal Notice, Brief, Reply Brief) Petition to Convert to a After Final Proprietary Information Provisional Application Power of Attorney, Revocation Affidavits/declaration(s) Status Letter Change of Correspondence Address Other Enclosure(s) (please Extension of Time Request Terminal Disclaimer Identify below): Two References Express Abandonment Request Request for Refund Check in the amount of \$180.00 Return Receipt Postcard x Information Disclosure Statement CD, Number of CD(s) Certificate of Express Mailing Certified Copy of Priority Landscape Table on CD Document(s) Reply to Missing Parts/ Remarks Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name DARBY & DARBY P.C. Signature Printed name Stephanie R. Amoroso, Ph.D.

Reg. No.


51,401

April 22, 2005

Date

PTO/SB/17 (12-04v2)
Approved for use through 7/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number.

Effective on 12/08/2004.			Co	mplete if Know	/n
Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R.	R. 4818).	Application Nun	nber	10/076,905	
FEE TRANSMITTAL		Filing Date		February 14, 2	2002
For FY 2005			Ze'ev Ronai		
	Examiner Name	Examiner Name S. L. Rawlings			
X Applicant claims small entity status. See 37 CFR 1.27	,	Art Unit 1642			
TOTAL AMOUNT OF PAYMENT (\$) 180.00		Attorney Docket	Attorney Docket No. 02420/100I249-US2		
METHOD OF PAYMENT (check all that apply)			'		
X Check Credit Card Money Order	Nor	ne Other (please ide	ntify):	
Deposit Account Deposit Account Number: 04-0100 D	eposit Acc	ount Name:		Darby & Darby	P.C.
For the above-identified deposit account, the Di	irector is	hereby authorize	d to: (ch	eck all that apply)	
Charge fee(s) indicated below		Charge	e fee(s) ir	ndicated below, e	xcept for the filing fee
Charge any additional fee(s) or underpayr fee(s) under 37 CFR 1.16 and 1.17	ment of	x Credit	any over	payments	
FEE CALCULATION					
1. BASIC FILING, SEARCH, AND EXAMINATION FEE	S				
FILING FEES Small Entity Application Type Fee (\$)	SE/	ARCH FEES Small Entity Fee (\$)	EXAMI	INATION FEES Small Entity Fee (\$)	Fees Paid (\$)
Utility 300 150	500	250	200	100	rees raid (4)
Design 200 100	100	50	130	65	
Plant 200 100	300	150	160	80	
Reissue 300 150	500	250	600	300	
Provisional 200 100	0	0	0	0	
2. EXCESS CLAIM FEES					Small Entity
Fee Description Each claim over 20 (including Reissues)					Fee (\$) Fee (\$) 50 25
Each independent claim over 3 (including Reissues)					200 100
Multiple dependent claims					360 180
Total Claims	Fee F	Paid (\$)	<u>N</u>	Multiple Depende	ent Claims
x =			E	ee (\$)	Fee Paid (\$)
Indep. Claims 3 -6 = Extra Claims x Fee (\$) =	Fee F	Paid (\$)			 -
3. APPLICATION SIZE FEE If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).					
		dditional 50 or frac			Fee Paid (\$)
4. OTHER FEE(S) Non-English Specification, \$130 fee (no small ent				,	Fees Paid (\$)
Other (e.g., late filing surcharge): 1806 Submission	•	•	isclosur	e Statement	180.00
SUBMITTED BY /// , //					
Signature Vite Shurthum		Registration No. (Attorney/Agent)	51,401	Telephone	(212) 409-3790
Name (Print/Type) Stephanie R. Amoroso, Ph.D.				Date	April 22, 2005



Docket No.: 02420/100I249-US2 (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Ze'ev Ronai

Application No.: 10/076,905

TREAT CANCER

Confirmation No.: 1884

Filed: February 14, 2002

Art Unit: 1642

For:

INHIBITION OF ATF2 ACTIVITY TO

Examiner: S. L. Rawlings

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

A copy of each document on the PTO/SB/08 is attached.

8

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Our check in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p) is enclosed. The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: April 22, 2005

Respectfully, submitted,

By / fe Sunt

Stephanie R. Amoroso, Ph.D. Registration No.: 51,401

DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700

(212) 527-7701 (Fax)

Attorneys/Agents For Applicant

Application No. (if known): 10/076,905

Attorney Docket No.: 02420/1001249-US2

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. 2 562101 an envelope addressed to:

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

22 April **29**, 2005

Date

Signature
Signature
Typed or printed name of person signing Certificate

N/A
Registration Number, if applicable

(212) 527-7700 Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Transmittal Form

Supplemental Information Disclosure Statement

IDS Citation by Applicant (PTO SB-08)

Two References
Fee Transmittal (1 page)

Check in the amount of \$180.00

Certificate of Express Mailing



PTO/S8/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERC under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control numbe

Substitute for form 1449A/B/PTO				Complete if Known		
Substitute 15 to 1				Application Number	10/076,905	
11	IFORMATION	I DI	SCLOSURE	Filing Date	February 14, 2002	
STATEMENT BY APPLICANT			APPLICANT	First Named Inventor	Ze'ev Ronai	
				Art Unit	1642	
(Use as many sheets as necessary)			necessary)	Examiner Name	S. L. Rawlings	
Sheet	1	of	1	Attorney Docket Number	02420/100l249-US2	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁴ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicants unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Inter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the erign of the Emperor must precede the serial number of the patent document. *Stind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is a statched.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, calalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	CA	Cho et al., TIP49b, a Regulator of Activating Transcription Factor 2 Response to Stress and DNA damage. Mol. Cell. Biol. 2001. 21: 8398-8413.	
	СВ	Buschmann et al., Amino-terminal-derived JNK Fragment Alters Expression and Activity of c-Jun, ATF2, and p56 and Increases H202-induced Cell Death, J. Biol. Chem. 2000; 278: 16590-96.	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

{W:\024	Date	
	Considered	
20/10011	 Toorisidered	

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.